- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
UK MHRA approved Foundayo for commercialization, marking a significant market entry point in the global obesity drug competition.
8 reports, 1 independent
Updated Aug 19
Gone quiet
- Reports
- 8
- Developments
- 1
- Repetition
- 88%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UK MHRA approved Foundayo for commercialization, marking a significant market entry point in the global obesity drug competition.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Also in this story
- Eli Lilly and Novo Nordisk are leading the weight management market, with plans to seek label expansion applications in Europe.
- Eli Lilly's clinical trial results showed their pill was less effective than Wegovy, leading to market discussion among analysts and market watchers like Mizuho.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Teva obtained FDA approval for a generic drug, challenging Novo Nordisk's market share in the GLP-1RA space.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly's Foundayo is undergoing global market rollout, including a launch in the UK, ongoing review in the EU, and utilization in the US.
- RSM UK surveyed consumer interest in weight-loss pills.
- Market expectations are shifting toward long-acting injectable technologies, accompanied by partnership terminations affecting drug development rights in the obesity drug sector.
- Novo announced a strategic partnership with Anthropic, Mike Doustdar was installed as CEO, and Eli Lilly gained market share in obesity care.